Teva Pharmaceutical Industries (NYSE:TEVA) EVP Sells $3,633,798.30 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Eliyahu Sharon Kalif sold 106,563 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the completion of the sale, the executive vice president directly owned 65,621 shares of the company’s stock, valued at approximately $2,237,676.10. This trade represents a 61.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Eliyahu Sharon Kalif also recently made the following trade(s):

• On Thursday, May 14th, Eliyahu Sharon Kalif sold 153,251 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $35.61, for a total transaction of $5,457,268.11.

Teva Pharmaceutical Industries Stock Down 2.8%

TEVA opened at $33.66 on Tuesday. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35. The company has a market capitalization of $38.70 billion, a PE ratio of 25.30, a PEG ratio of 3.53 and a beta of 0.84. The firm’s 50 day simple moving average is $33.35 and its two-hundred day simple moving average is $32.08.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The firm had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. As a group, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Piper Sandler restated an “overweight” rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Bank of America boosted their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Finally, UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.78.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently added to or reduced their stakes in TEVA. Militia Capital Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the first quarter worth $3,497,000. Avidity Partners Management LP increased its holdings in Teva Pharmaceutical Industries by 7.9% in the 1st quarter. Avidity Partners Management LP now owns 450,100 shares of the company’s stock valued at $13,557,000 after acquiring an additional 32,800 shares during the last quarter. Alpine Woods Capital Investors LLC lifted its stake in Teva Pharmaceutical Industries by 98.3% in the 1st quarter. Alpine Woods Capital Investors LLC now owns 29,424 shares of the company’s stock worth $886,000 after purchasing an additional 14,587 shares in the last quarter. Glenmede Trust Co. NA lifted its stake in Teva Pharmaceutical Industries by 486.3% in the 1st quarter. Glenmede Trust Co. NA now owns 53,377 shares of the company’s stock worth $1,608,000 after purchasing an additional 44,273 shares in the last quarter. Finally, Axiom Investment Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at about $965,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.